#  @Anthony_TayIor tony tony posts on X about $crvs, $cmps, ss, arm the most. They currently have [---] followers and [--] posts still getting attention that total [---] engagements in the last [--] hours. ### Engagements: [---] [#](/creator/twitter::2580235585/interactions)  - [--] Week [-----] +1,322% - [--] Month [------] +59% ### Mentions: [--] [#](/creator/twitter::2580235585/posts_active)  - [--] Week [--] +350% - [--] Month [--] +189% ### Followers: [---] [#](/creator/twitter::2580235585/followers)  - [--] Week [---] +3.20% - [--] Month [---] +40% ### CreatorRank: [---------] [#](/creator/twitter::2580235585/influencer_rank)  ### Social Influence **Social category influence** [stocks](/list/stocks) [social networks](/list/social-networks) [technology brands](/list/technology-brands) **Social topic influence** [$crvs](/topic/$crvs), [$cmps](/topic/$cmps) #11, [ss](/topic/ss), [arm](/topic/arm), [$tenx](/topic/$tenx), [tenx](/topic/tenx), [i am](/topic/i-am), [c3](/topic/c3), [strong](/topic/strong), [$rgnx](/topic/$rgnx) **Top accounts mentioned or mentioned by** [@amaymd](/creator/undefined) [@hothomaswphelps](/creator/undefined) [@biotechautist](/creator/undefined) [@godelterminal](/creator/undefined) [@tweetawaydk](/creator/undefined) [@cluelessbio](/creator/undefined) [@catalystpharma](/creator/undefined) [@jeremyfalmouth](/creator/undefined) [@biotechbaboon](/creator/undefined) [@houndcl](/creator/undefined) **Top assets mentioned** [COMPASS Pathways plc (CMPS)](/topic/$cmps) [Ocular Therapeutix, Inc. (OCUL)](/topic/$ocul) [Fractyl Health, Inc. (GUTS)](/topic/$guts) ### Top Social Posts Top posts by engagements in the last [--] hours "An Argument in favor of $GUTS [--]. Persons with limiting side effects [--]. Nonresponders to max dose [--]. Contraindications to GLPs (hx of pancreatitis) [--]. Pill burden [--]. Lack of MACE improvement with GLP induced weight loss (Preserved by bariatric surgery possibly by $GUTS" [X Link](https://x.com/Anthony_TayIor/status/2008543653833347456) 2026-01-06T14:18Z [---] followers, [---] engagements "@BiotechAutist @GodelTerminal PARASOL didn't exist when the FDA made their original ruling and has since validated the reductions in proteinuria are strong predictors of progression of kidney disease. The independent duplex (cont.)" [X Link](https://x.com/Anthony_TayIor/status/2008949779313606765) 2026-01-07T17:12Z [--] followers, [---] engagements "$TENX is a zero. This medication has no utility. You treat type [--] PH by modulating the neurohormonal bombardment of the LV to prevent fibrosis necrosis and apoptosis of cardiac myocytes. Not by congesting the intestines which PO loop diuretic failure @A_May_MD" [X Link](https://x.com/anyuser/status/2011503060082622634) 2026-01-14T18:17Z [---] followers, 11.1K engagements "@A_May_MD Neurohormonal modulation will improve LV function and pulmonary pressures even without poisoning the loop of henle Add to it the long term protective effects against further remodeling and MACE. $TENX doesn't even have a role in acute exacerbations as far as I am concerned" [X Link](https://x.com/anyuser/status/2011503625911021872) 2026-01-14T18:20Z [---] followers, [----] engagements "$CRVS I've crunched some numbers for cohort [--] data read out and think bad data is almost impossible. By pooling c4 with c3 (which used the same dosing and are comparable 1+2 did not) even a strong pbo response still allows for SS. https://readjudication.com/2026/01/14/biostats_crvs_c4pooled/ https://readjudication.com/2026/01/14/biostats_crvs_c4pooled/" [X Link](https://x.com/anyuser/status/2011618098722586989) 2026-01-15T01:55Z [---] followers, [----] engagements "Even looking at C4 alone good data should be very attainable if we assume historical pbo response to easi [--] of 12.5% the mean pbo easi is 33.3% . You only need a tx arm response of 55% for SS. C3 had 68%. To me good data is a shoe in $CRVS @HOThomasWPhelps" [X Link](https://x.com/anyuser/status/2011618100538720604) 2026-01-15T01:55Z [---] followers, [----] engagements "@A_May_MD I don't follow because type [--] PH is caused by HF we have GDMT which improves the literal underlying mechanism of heart failure (gotta address comorbidities too) and by proxy pulm pressure.There will always be profiteers trying to edge into the market. But we know how to tx HF" [X Link](https://x.com/Anthony_TayIor/status/2011623437836697755) 2026-01-15T02:16Z [--] followers, [---] engagements "@BiotechAutist I have similar sentiments. Really like $RGNX to get approved. Very robust manufacturing capabilities this will validate their gene platform. Their other two assets are the important ones" [X Link](https://x.com/Anthony_TayIor/status/2012225372339814656) 2026-01-16T18:08Z [--] followers, [---] engagements "@cluelessbio Where are the events then. Saying you have a 76% ppv to have a 50% chance of having a dili makes it 38% odds are good. These events could not manifest. There is no itk expression in hepatocytes. Other selective kinases do not have severe liver events. We've seen nothing to date" [X Link](https://x.com/Anthony_TayIor/status/2006721439366525301) 2026-01-01T13:37Z [---] followers, [---] engagements "$CRVS gets bought out for sure right 3-4b. @HOThomasWPhelps" [X Link](https://x.com/anyuser/status/2013780272018252182) 2026-01-21T01:06Z [---] followers, [---] engagements "On Monday I am going to quadruple my long position in $RGNX. My arch-nemesis @BiotechAutist going short concretizes the idea that I am on the correct side. All of my insights are posted on @GodelTerminal" [X Link](https://x.com/anyuser/status/2015220628261892168) 2026-01-25T00:30Z [---] followers, [----] engagements "1/4 $OCUL Interesting discussions today. One consideration being eyelea's inhibitory concentration lasting to [--] weeks. That leaves a [--] month window of separation between Axpaxli and their Eylea control. https://pmc.ncbi.nlm.nih.gov/articles/PMC10220677/ https://pmc.ncbi.nlm.nih.gov/articles/PMC10220677/" [X Link](https://x.com/anyuser/status/2016320856096473378) 2026-01-28T01:22Z [---] followers, [----] engagements "This to me suggests that the rescues are lower than what you would expect if it were Eylea in both arms AND occurring at around the [--] mo window suggesting control arm is failing and there will be significant separation" [X Link](https://x.com/anyuser/status/2016320861695815956) 2026-01-28T01:22Z [---] followers, [---] engagements "@CatalystPharma @JeremyFalmouth [--] letter loss the is the rescue criteria and what they define as preservation of visual acuity which is the primary endpoint. In some sense getting rescued means you miss the endpoint. The statistical significance dictates the superiority" [X Link](https://x.com/Anthony_TayIor/status/2017168492710056116) 2026-01-30T09:30Z [---] followers, [--] engagements "$CMPS Short the 'Shrooms I'll start by setting the table here. In [----] NEJM published this article on psilocybin for treatment-resistant depression. Only the 25mg dose worked at [--] weeks but failed by [--] weeks. https://www.nejm.org/doi/full/10.1056/NEJMoa2206443 https://www.nejm.org/doi/full/10.1056/NEJMoa2206443" [X Link](https://x.com/anyuser/status/2021398489528520826) 2026-02-11T01:38Z [---] followers, [---] engagements "There is a clear lack of durability of the psilocybin treatment Durability is sort've the selling point of $CMPS by the way. They're hoping to leverage the magic of neuroplasticity to improve depression" [X Link](https://x.com/Anthony_TayIor/status/2021398491348730080) 2026-02-11T01:38Z [---] followers, [---] engagements "However the cause of depression is heterogeneous and if driven by more environmental factors is less likely (conceptually) to be responsive to neuroplastic changes - especially the treatment resistant type which is whom the study is on" [X Link](https://x.com/Anthony_TayIor/status/2021398493416522030) 2026-02-11T01:38Z [---] followers, [--] engagements "The ph2 study also allowed participants to start new antidepressants if they were needed which was the same numerically across all groups but quite a few (38% - who need rescue meds) and started later in the [--] mg group around week 6" [X Link](https://x.com/Anthony_TayIor/status/2021398495723405415) 2026-02-11T01:38Z [---] followers, [--] engagements "This is ominous for COMP005 as the part A data looked up until week [--] (not a coincidence). It would seem this is where things are as good as they get before the treatment arm starts regressing to the depression control" [X Link](https://x.com/Anthony_TayIor/status/2021398497925398939) 2026-02-11T01:38Z [---] followers, [--] engagements "At [--] weeks [---] showed a difference of [----] points the ph2 study from NEJM showed a differnce [---] points at [--] weeks Double Around [---] pts is considered to be meaningful. COMP005 has already underachieved and the stock dumped after those results came out -50%" [X Link](https://x.com/Anthony_TayIor/status/2021398500160962578) 2026-02-11T01:38Z [---] followers, [--] engagements "$CMPS alsodid not give the actual MADRs LSM numbers for each group. why is that They also have not reported any information on response (50% reduction) or remission (10 MADRS) - is this because they are not achieving it" [X Link](https://x.com/anyuser/status/2021398503008895292) 2026-02-11T01:38Z [---] followers, [---] engagements "There is nothing I like about the data that I've seen so far and I fully expect $CMPS to try to spin bad data to sound positive. If the data was positive we'd have the LSM the response and remission numbers" [X Link](https://x.com/anyuser/status/2021398505487814929) 2026-02-11T01:38Z [---] followers, [---] engagements "@TweetAwayDK In my opinion it doesn't work. I believe any early change we see is based patient expectations environmental factors and therapy support. In the ph3 trial the early effect is marginal and they won't tell us true response and remission numbers" [X Link](https://x.com/Anthony_TayIor/status/2021584577211310243) 2026-02-11T13:58Z [---] followers, [--] engagements "$CMPS Short the 'Shrooms I'll start by setting the table here. In [----] NEJM published this article on psilocybin for treatment-resistant depression. Only the 25mg dose worked at [--] weeks but failed by [--] weeks. https://www.nejm.org/doi/full/10.1056/NEJMoa2206443 https://www.nejm.org/doi/full/10.1056/NEJMoa2206443" [X Link](https://x.com/anyuser/status/2021398489528520826) 2026-02-11T01:38Z [---] followers, [---] engagements "$CMPS alsodid not give the actual MADRs LSM numbers for each group. why is that They also have not reported any information on response (50% reduction) or remission (10 MADRS) - is this because they are not achieving it" [X Link](https://x.com/anyuser/status/2021398503008895292) 2026-02-11T01:38Z [---] followers, [---] engagements "There is nothing I like about the data that I've seen so far and I fully expect $CMPS to try to spin bad data to sound positive. If the data was positive we'd have the LSM the response and remission numbers" [X Link](https://x.com/anyuser/status/2021398505487814929) 2026-02-11T01:38Z [---] followers, [---] engagements "1/4 $OCUL Interesting discussions today. One consideration being eyelea's inhibitory concentration lasting to [--] weeks. That leaves a [--] month window of separation between Axpaxli and their Eylea control. https://pmc.ncbi.nlm.nih.gov/articles/PMC10220677/ https://pmc.ncbi.nlm.nih.gov/articles/PMC10220677/" [X Link](https://x.com/anyuser/status/2016320856096473378) 2026-01-28T01:22Z [---] followers, [----] engagements "This only leaves the remaining three months of the trial for drop off of the control to occur. However the management has been 'excited' by the unmasked (rescue) data they have seen specifically mentioning the cadence" [X Link](https://x.com/anyuser/status/2016320859678359893) 2026-01-28T01:22Z [---] followers, [---] engagements "This to me suggests that the rescues are lower than what you would expect if it were Eylea in both arms AND occurring at around the [--] mo window suggesting control arm is failing and there will be significant separation" [X Link](https://x.com/anyuser/status/2016320861695815956) 2026-01-28T01:22Z [---] followers, [---] engagements "On Monday I am going to quadruple my long position in $RGNX. My arch-nemesis @BiotechAutist going short concretizes the idea that I am on the correct side. All of my insights are posted on @GodelTerminal" [X Link](https://x.com/anyuser/status/2015220628261892168) 2026-01-25T00:30Z [---] followers, [----] engagements "$CRVS is still undervalued (by appx $10b) I think they get bought out for $4-5b" [X Link](https://x.com/anyuser/status/2013787268171932088) 2026-01-21T01:34Z [---] followers, [---] engagements "$CRVS gets bought out for sure right 3-4b. @HOThomasWPhelps" [X Link](https://x.com/anyuser/status/2013780272018252182) 2026-01-21T01:06Z [---] followers, [---] engagements "$CRVS I've crunched some numbers for cohort [--] data read out and think bad data is almost impossible. By pooling c4 with c3 (which used the same dosing and are comparable 1+2 did not) even a strong pbo response still allows for SS. https://readjudication.com/2026/01/14/biostats_crvs_c4pooled/ https://readjudication.com/2026/01/14/biostats_crvs_c4pooled/" [X Link](https://x.com/anyuser/status/2011618098722586989) 2026-01-15T01:55Z [---] followers, [----] engagements "Even looking at C4 alone good data should be very attainable if we assume historical pbo response to easi [--] of 12.5% the mean pbo easi is 33.3% . You only need a tx arm response of 55% for SS. C3 had 68%. To me good data is a shoe in $CRVS @HOThomasWPhelps" [X Link](https://x.com/anyuser/status/2011618100538720604) 2026-01-15T01:55Z [---] followers, [----] engagements "@HOThomasWPhelps If [--] pbo patients hit easi [--] (18%) you need a treatment arm mean easi of [--] for SS" [X Link](https://x.com/anyuser/status/2011618836827832614) 2026-01-15T01:57Z [---] followers, [---] engagements "$TENX is a zero. This medication has no utility. You treat type [--] PH by modulating the neurohormonal bombardment of the LV to prevent fibrosis necrosis and apoptosis of cardiac myocytes. Not by congesting the intestines which PO loop diuretic failure @A_May_MD" [X Link](https://x.com/anyuser/status/2011503060082622634) 2026-01-14T18:17Z [---] followers, 11.1K engagements "@A_May_MD The original tweet should read *leads to PO loop failure*" [X Link](https://x.com/anyuser/status/2011503860968460567) 2026-01-14T18:21Z [---] followers, [----] engagements "@A_May_MD Neurohormonal modulation will improve LV function and pulmonary pressures even without poisoning the loop of henle Add to it the long term protective effects against further remodeling and MACE. $TENX doesn't even have a role in acute exacerbations as far as I am concerned" [X Link](https://x.com/anyuser/status/2011503625911021872) 2026-01-14T18:20Z [---] followers, [----] engagements Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing
@Anthony_TayIor tony
tony posts on X about $crvs, $cmps, ss, arm the most. They currently have [---] followers and [--] posts still getting attention that total [---] engagements in the last [--] hours.
Engagements: [---] #
- [--] Week [-----] +1,322%
- [--] Month [------] +59%
Mentions: [--] #
- [--] Week [--] +350%
- [--] Month [--] +189%
Followers: [---] #
- [--] Week [---] +3.20%
- [--] Month [---] +40%
CreatorRank: [---------] #
Social Influence
Social category influence stocks social networks technology brands
Social topic influence $crvs, $cmps #11, ss, arm, $tenx, tenx, i am, c3, strong, $rgnx
Top accounts mentioned or mentioned by @amaymd @hothomaswphelps @biotechautist @godelterminal @tweetawaydk @cluelessbio @catalystpharma @jeremyfalmouth @biotechbaboon @houndcl
Top assets mentioned COMPASS Pathways plc (CMPS) Ocular Therapeutix, Inc. (OCUL) Fractyl Health, Inc. (GUTS)
Top Social Posts
Top posts by engagements in the last [--] hours
"An Argument in favor of $GUTS [--]. Persons with limiting side effects [--]. Nonresponders to max dose [--]. Contraindications to GLPs (hx of pancreatitis) [--]. Pill burden [--]. Lack of MACE improvement with GLP induced weight loss (Preserved by bariatric surgery possibly by $GUTS"
X Link 2026-01-06T14:18Z [---] followers, [---] engagements
"@BiotechAutist @GodelTerminal PARASOL didn't exist when the FDA made their original ruling and has since validated the reductions in proteinuria are strong predictors of progression of kidney disease. The independent duplex (cont.)"
X Link 2026-01-07T17:12Z [--] followers, [---] engagements
"$TENX is a zero. This medication has no utility. You treat type [--] PH by modulating the neurohormonal bombardment of the LV to prevent fibrosis necrosis and apoptosis of cardiac myocytes. Not by congesting the intestines which PO loop diuretic failure @A_May_MD"
X Link 2026-01-14T18:17Z [---] followers, 11.1K engagements
"@A_May_MD Neurohormonal modulation will improve LV function and pulmonary pressures even without poisoning the loop of henle Add to it the long term protective effects against further remodeling and MACE. $TENX doesn't even have a role in acute exacerbations as far as I am concerned"
X Link 2026-01-14T18:20Z [---] followers, [----] engagements
"$CRVS I've crunched some numbers for cohort [--] data read out and think bad data is almost impossible. By pooling c4 with c3 (which used the same dosing and are comparable 1+2 did not) even a strong pbo response still allows for SS. https://readjudication.com/2026/01/14/biostats_crvs_c4pooled/ https://readjudication.com/2026/01/14/biostats_crvs_c4pooled/"
X Link 2026-01-15T01:55Z [---] followers, [----] engagements
"Even looking at C4 alone good data should be very attainable if we assume historical pbo response to easi [--] of 12.5% the mean pbo easi is 33.3% . You only need a tx arm response of 55% for SS. C3 had 68%. To me good data is a shoe in $CRVS @HOThomasWPhelps"
X Link 2026-01-15T01:55Z [---] followers, [----] engagements
"@A_May_MD I don't follow because type [--] PH is caused by HF we have GDMT which improves the literal underlying mechanism of heart failure (gotta address comorbidities too) and by proxy pulm pressure.There will always be profiteers trying to edge into the market. But we know how to tx HF"
X Link 2026-01-15T02:16Z [--] followers, [---] engagements
"@BiotechAutist I have similar sentiments. Really like $RGNX to get approved. Very robust manufacturing capabilities this will validate their gene platform. Their other two assets are the important ones"
X Link 2026-01-16T18:08Z [--] followers, [---] engagements
"@cluelessbio Where are the events then. Saying you have a 76% ppv to have a 50% chance of having a dili makes it 38% odds are good. These events could not manifest. There is no itk expression in hepatocytes. Other selective kinases do not have severe liver events. We've seen nothing to date"
X Link 2026-01-01T13:37Z [---] followers, [---] engagements
"$CRVS gets bought out for sure right 3-4b. @HOThomasWPhelps"
X Link 2026-01-21T01:06Z [---] followers, [---] engagements
"On Monday I am going to quadruple my long position in $RGNX. My arch-nemesis @BiotechAutist going short concretizes the idea that I am on the correct side. All of my insights are posted on @GodelTerminal"
X Link 2026-01-25T00:30Z [---] followers, [----] engagements
"1/4 $OCUL Interesting discussions today. One consideration being eyelea's inhibitory concentration lasting to [--] weeks. That leaves a [--] month window of separation between Axpaxli and their Eylea control. https://pmc.ncbi.nlm.nih.gov/articles/PMC10220677/ https://pmc.ncbi.nlm.nih.gov/articles/PMC10220677/"
X Link 2026-01-28T01:22Z [---] followers, [----] engagements
"This to me suggests that the rescues are lower than what you would expect if it were Eylea in both arms AND occurring at around the [--] mo window suggesting control arm is failing and there will be significant separation"
X Link 2026-01-28T01:22Z [---] followers, [---] engagements
"@CatalystPharma @JeremyFalmouth [--] letter loss the is the rescue criteria and what they define as preservation of visual acuity which is the primary endpoint. In some sense getting rescued means you miss the endpoint. The statistical significance dictates the superiority"
X Link 2026-01-30T09:30Z [---] followers, [--] engagements
"$CMPS Short the 'Shrooms I'll start by setting the table here. In [----] NEJM published this article on psilocybin for treatment-resistant depression. Only the 25mg dose worked at [--] weeks but failed by [--] weeks. https://www.nejm.org/doi/full/10.1056/NEJMoa2206443 https://www.nejm.org/doi/full/10.1056/NEJMoa2206443"
X Link 2026-02-11T01:38Z [---] followers, [---] engagements
"There is a clear lack of durability of the psilocybin treatment Durability is sort've the selling point of $CMPS by the way. They're hoping to leverage the magic of neuroplasticity to improve depression"
X Link 2026-02-11T01:38Z [---] followers, [---] engagements
"However the cause of depression is heterogeneous and if driven by more environmental factors is less likely (conceptually) to be responsive to neuroplastic changes - especially the treatment resistant type which is whom the study is on"
X Link 2026-02-11T01:38Z [---] followers, [--] engagements
"The ph2 study also allowed participants to start new antidepressants if they were needed which was the same numerically across all groups but quite a few (38% - who need rescue meds) and started later in the [--] mg group around week 6"
X Link 2026-02-11T01:38Z [---] followers, [--] engagements
"This is ominous for COMP005 as the part A data looked up until week [--] (not a coincidence). It would seem this is where things are as good as they get before the treatment arm starts regressing to the depression control"
X Link 2026-02-11T01:38Z [---] followers, [--] engagements
"At [--] weeks [---] showed a difference of [----] points the ph2 study from NEJM showed a differnce [---] points at [--] weeks Double Around [---] pts is considered to be meaningful. COMP005 has already underachieved and the stock dumped after those results came out -50%"
X Link 2026-02-11T01:38Z [---] followers, [--] engagements
"$CMPS alsodid not give the actual MADRs LSM numbers for each group. why is that They also have not reported any information on response (50% reduction) or remission (10 MADRS) - is this because they are not achieving it"
X Link 2026-02-11T01:38Z [---] followers, [---] engagements
"There is nothing I like about the data that I've seen so far and I fully expect $CMPS to try to spin bad data to sound positive. If the data was positive we'd have the LSM the response and remission numbers"
X Link 2026-02-11T01:38Z [---] followers, [---] engagements
"@TweetAwayDK In my opinion it doesn't work. I believe any early change we see is based patient expectations environmental factors and therapy support. In the ph3 trial the early effect is marginal and they won't tell us true response and remission numbers"
X Link 2026-02-11T13:58Z [---] followers, [--] engagements
"$CMPS Short the 'Shrooms I'll start by setting the table here. In [----] NEJM published this article on psilocybin for treatment-resistant depression. Only the 25mg dose worked at [--] weeks but failed by [--] weeks. https://www.nejm.org/doi/full/10.1056/NEJMoa2206443 https://www.nejm.org/doi/full/10.1056/NEJMoa2206443"
X Link 2026-02-11T01:38Z [---] followers, [---] engagements
"$CMPS alsodid not give the actual MADRs LSM numbers for each group. why is that They also have not reported any information on response (50% reduction) or remission (10 MADRS) - is this because they are not achieving it"
X Link 2026-02-11T01:38Z [---] followers, [---] engagements
"There is nothing I like about the data that I've seen so far and I fully expect $CMPS to try to spin bad data to sound positive. If the data was positive we'd have the LSM the response and remission numbers"
X Link 2026-02-11T01:38Z [---] followers, [---] engagements
"1/4 $OCUL Interesting discussions today. One consideration being eyelea's inhibitory concentration lasting to [--] weeks. That leaves a [--] month window of separation between Axpaxli and their Eylea control. https://pmc.ncbi.nlm.nih.gov/articles/PMC10220677/ https://pmc.ncbi.nlm.nih.gov/articles/PMC10220677/"
X Link 2026-01-28T01:22Z [---] followers, [----] engagements
"This only leaves the remaining three months of the trial for drop off of the control to occur. However the management has been 'excited' by the unmasked (rescue) data they have seen specifically mentioning the cadence"
X Link 2026-01-28T01:22Z [---] followers, [---] engagements
"This to me suggests that the rescues are lower than what you would expect if it were Eylea in both arms AND occurring at around the [--] mo window suggesting control arm is failing and there will be significant separation"
X Link 2026-01-28T01:22Z [---] followers, [---] engagements
"On Monday I am going to quadruple my long position in $RGNX. My arch-nemesis @BiotechAutist going short concretizes the idea that I am on the correct side. All of my insights are posted on @GodelTerminal"
X Link 2026-01-25T00:30Z [---] followers, [----] engagements
"$CRVS is still undervalued (by appx $10b) I think they get bought out for $4-5b"
X Link 2026-01-21T01:34Z [---] followers, [---] engagements
"$CRVS gets bought out for sure right 3-4b. @HOThomasWPhelps"
X Link 2026-01-21T01:06Z [---] followers, [---] engagements
"$CRVS I've crunched some numbers for cohort [--] data read out and think bad data is almost impossible. By pooling c4 with c3 (which used the same dosing and are comparable 1+2 did not) even a strong pbo response still allows for SS. https://readjudication.com/2026/01/14/biostats_crvs_c4pooled/ https://readjudication.com/2026/01/14/biostats_crvs_c4pooled/"
X Link 2026-01-15T01:55Z [---] followers, [----] engagements
"Even looking at C4 alone good data should be very attainable if we assume historical pbo response to easi [--] of 12.5% the mean pbo easi is 33.3% . You only need a tx arm response of 55% for SS. C3 had 68%. To me good data is a shoe in $CRVS @HOThomasWPhelps"
X Link 2026-01-15T01:55Z [---] followers, [----] engagements
"@HOThomasWPhelps If [--] pbo patients hit easi [--] (18%) you need a treatment arm mean easi of [--] for SS"
X Link 2026-01-15T01:57Z [---] followers, [---] engagements
"$TENX is a zero. This medication has no utility. You treat type [--] PH by modulating the neurohormonal bombardment of the LV to prevent fibrosis necrosis and apoptosis of cardiac myocytes. Not by congesting the intestines which PO loop diuretic failure @A_May_MD"
X Link 2026-01-14T18:17Z [---] followers, 11.1K engagements
"@A_May_MD The original tweet should read leads to PO loop failure"
X Link 2026-01-14T18:21Z [---] followers, [----] engagements
"@A_May_MD Neurohormonal modulation will improve LV function and pulmonary pressures even without poisoning the loop of henle Add to it the long term protective effects against further remodeling and MACE. $TENX doesn't even have a role in acute exacerbations as far as I am concerned"
X Link 2026-01-14T18:20Z [---] followers, [----] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing